According to the data, alterations in the BCR-ABL gene, which is connected with the drug-binding area, frequently result in imatinib resistance during CML chemotherapy [54, 55]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.